Interferon α extends the survival of human myeloma cells through an upregulation of the Mcl-1 anti-apoptotic molecule

British Journal of Haematology

Volumn 112, Issue 2, 2001, Pages 358-363

  Puthier, Denis ^a   Thabard, Wilfrid ^a   Rapp, Marie José ^b   Etrillard, Marguerite ^a   Harousseau, Jean Luc ^b   Bataille, Régis ^a   Amiot, Martine ^a  

^a INSTITUT DE BIOLOGIE   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

IFN ; IL 6; Mcl 1; Multiple myeloma; STAT3

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 6; JANUS KINASE; PROTEIN BCL 2; PROTEIN MCL 1; STAT3 PROTEIN;

ARTICLE; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

APOPTOSIS; DNA-BINDING PROTEINS; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-6; MULTIPLE MYELOMA; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED;

EID: 0035127222     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.02575.x     Document Type: Article

References (26)

1. Reversal of EBV immortalization precedes apoptosis in IL-6-induced human B cell terminal differentiation
2. Dissociation between IFN-alpha induced anti-viral and growth signalling pathways
3. Multiple myeloma
4. Viewpoint on the impact of interferon in the treatment of multiple myeloma: Benefit for a small proportion of patients
5. Development of aggressive plasma cell leukaemia under interferon-alpha therapy
6. The effect of alpha and gamma-interferon on proliferation and production of IgE and beta 2-microglobulin in the human myeloma cell line U-266 and in an alpha-interferon resistant U-266 subline
7. Stat 3 as an oncogene
8. Constitutive activation of Stat 3 signalling confers resistance to apoptosis in human U266 myeloma cells
9. Phase I-II trial of interferon-alpha 2b by continuous subcutaneous infusion over 28 days
10. Staging and kinetics of multiple myeloma
11. Modulation of Apo-1/Fas (CD95)-induced programmed cell death in myeloma cells by interferon-alpha 2
12. Interferon-alpha activates signal transducers and activators of transcription 5 and 6 in Daudi cells
13. IFN-alpha is a survival factor for human myeloma cells and reduces dexamethasone-induced apoptosis
14. Cytokine therapeutics: Lessons from interferon alpha
15. Effects of interferon alpha on myeloma cells: Mechanisms of differential responsiveness
16. IFN-alpha induces autocrine production of IL-6 in myeloma cell lines
17. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse
18. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: Correlations with in vitro and in vivo chemoresponses
19. Interferon-alpha protects myeloma cell lines from dexamethasone-induced apoptosis
20. Expression of the Bcl-2 homologue Mcl-1 correlates with survival of peripheral blood B lymphocytes
21. Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells
22. IL-6 upregulates Mcl-1 in human myeloma cells through JAK/STAT rather than Ras/MAP kinase pathway
23. Plasma cell leukaemia with alpha-interferon therapy in myeloma
24. Bcl-x expression in multiple myeloma: Possible indicator of chemoresistance
25. Which myeloma patients benefit from interferon therapy? An overview of 24 randomized trials with 4000 patients
26. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma